Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Ratio (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Equity Ratio for 6 consecutive years, with 1.22 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 249.16% to 1.22 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.22 through Dec 2025, down 249.16% year-over-year, with the annual reading at 1.22 for FY2025, 249.16% down from the prior year.
  • Equity Ratio hit 1.22 in Q4 2025 for Insight Molecular Diagnostics, down from 0.21 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.82 in Q1 2021 to a low of 1.22 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.24 across 5 years, with a median of 0.37 in 2022.
  • Biggest five-year swings in Equity Ratio: surged 33.97% in 2021 and later crashed 251.34% in 2025.
  • Year by year, Equity Ratio stood at 0.41 in 2021, then decreased by 16.18% to 0.34 in 2022, then fell by 20.23% to 0.27 in 2023, then plummeted by 228.02% to 0.35 in 2024, then tumbled by 249.16% to 1.22 in 2025.
  • Business Quant data shows Equity Ratio for IMDX at 1.22 in Q4 2025, 0.21 in Q3 2025, and 0.02 in Q2 2025.